On Wednesday, in the course of afternoon trade, Shares of LinkedIn Corp (NYSE:LNKD), climbed 1.19%, and is now trading at $231.26.
Empire State Realty Trust, declared that LinkedIn Corporation (LNKD) is expanding its New York City headquarters by occupying an additional 130,000 square feet at the property.
The expansion in the “World’s Most Famous Building” will have LinkedIn encompassing the entire third and 26th floors, bringing the company’s total occupancy to 280,000 square feet on seven floors. LinkedIn first moved into the building in 2011.
LinkedIn Corporation, together with its auxiliaries, operates an online professional network worldwide. The company, through its proprietary platform, allows members to create, manage, and share their professional identity online; build and engage with their professional networks; access shared knowledge and insights; and find business opportunities.
During an Afternoon trade, Shares of PNC Financial Services Group Inc (NYSE:PNC), climbed 0.58%, and is now trading at $98.73.
The PNC Financial Services Group, stated net income of $1.0 billion, or $1.88 per diluted common share, for the second quarter of 2015 contrast with net income of $1.0 billion, or $1.75 per diluted common share, for the first quarter of 2015 and net income of $1.1 billion, or $1.85 per diluted common share, for the second quarter of 2014.
“PNC had a successful second quarter,” said William S. Demchak, chairman, president and chief executive officer. “We grew fee income on higher client activity, made positive progress on our planned precedingities and managed our expenses well despite low interest rates that continue to pressure net interest income industrywide.”
The PNC Financial Services Group, Inc. operates as a diversified financial services company in the United States. It operates through six segments: Retail Banking, Corporate & Institutional Banking, Asset Administration Group, Residential Mortgage Banking, BlackRock, and Non-Planned Assets Portfolio.
Shares of FedEx Corporation (NYSE:FDX), during its Wednesday’s current trading session raised 1.66%, and is now trading at $172.25.
FedEx Express, agreed to purchase 50 additional 767-300F aircraft from The Boeing Company as it continues to modernize its aircraft fleet to more effectively serve its customers. In addition to the 50 confirmed orders, FedEx also has options to purchase a total of 50 767F aircraft.
The 50 firm-order aircraft will be delivered from fiscal 2018 through fiscal 2023. Total capital spending for fiscal 2016 remains at $4.6 billion. The impact to capital spending in fiscal 2017 from this new order is immaterial. With this order, FedEx Express now holds a total of 106 firm orders for 767Fs from The Boeing Company through fiscal 2023.
FedEx Corporation provides transportation, e-commerce, and business services in the United States and internationally. The company’s FedEx Express segment provides various shipping services for the delivery of packages and freight; international trade services specializing in customs brokerage, and ocean and air freight forwarding services; international trade advisory services, such as assistance with the customs-trade partnership against terrorism program; and customs clearance services, in addition to global trade data, an information tool that allows customers to track and manage imports.
Finally, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), lost -0.12% at $0.12
Arena Pharmaceuticals, declared the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis. Discovered by Arena, APD334 is an oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in ulcerative colitis in addition to other autoimmune diseases.
“Important aims of pharmacotherapy for ulcerative colitis are to induce and maintain remission while improving the patient’s quality of life, and, based on the results from our Phase 1 program, we believe APD334 has the potential to achieve these aims,” said Jack Lief, Arena’s President and Chief Executive Officer. “In addition to ulcerative colitis, we believe APD334 could have utility for a variety of autoimmune diseases.”
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
